{
  "guideline": {
    "id": "PA166182741",
    "name": "Annotation of FDA Label for articaine / epinephrine and CYB5R3, G6PD",
    "source": "FDA",
    "version": 10,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182741",
    "relatedChemicals": [
      {
        "id": "PA166182783",
        "name": "articaine / epinephrine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA27331",
        "name": "cytochrome b5 reductase 3",
        "symbol": "CYB5R3"
      },
      {
        "id": "PA28469",
        "name": "glucose-6-phosphate dehydrogenase",
        "symbol": "G6PD"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166315142",
      "name": "Recommendation Annotation PA166315142",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182783",
          "name": "articaine / epinephrine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452245681,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Variable"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312427",
      "name": "Recommendation Annotation PA166312427",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182783",
          "name": "articaine / epinephrine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216726,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient with CNSHA"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312416",
      "name": "Recommendation Annotation PA166312416",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182783",
          "name": "articaine / epinephrine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216715,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Articaine HCl and Epinephrine (articaine hydrochloride and epinephrine bitartrate), NDA022466, Safco Dental Supply Co.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022466"
    }
  ],
  "version": "2024-02-29-20-19"
}